Business Context and Reporting Period
Company: Lifevantage Corp (LifeVantage)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008
Business Overview: LifeVantage primarily sells Protandim, a proprietary dietary supplement designed to increase antioxidant enzyme production. The company also sells an Omega 3 fish oil product, though sales have been negligible. Operations rely heavily on outsourced manufacturing and fulfillment. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2007 |
|---|---|---|---|
| Net Sales | $578,457 | $1,851,959 | $1,603,733 |
| Gross Profit | $450,911 | $1,488,874 | $1,240,411 |
| Gross Margin % | 78% | 80% | 77% |
| Operating Expenses | $924,102 | $2,015,638 | $1,864,938 |
| Operating Loss | $(473,191) | $(526,764) | $(624,527) |
| Net Loss | $(566,014) | $(697,149) | $(700,483) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.03) | $(0.03) |
Liquidity and Balance Sheet Highlights (as of Dec 31, 2008)
- Cash and Cash Equivalents: $99,340 (Decreased from $196,883 at June 30, 2008).
- Marketable Securities: $750,000 (Available for sale; includes Auction Rate Preferred Securities).
- Total Current Assets: $1,272,873.
- Total Current Liabilities: $740,540.
- Working Capital: Approximately $532,000.
- Revolving Line of Credit: $250,086 outstanding (Collateralized by marketable securities).
- Convertible Debt: $307,039 (Long-term liability).
- Accumulated Deficit: $(15,455,510).
Material Changes vs. Prior Period
- Revenue Recognition Adjustment: A significant portion of the six-month revenue ($511,000) consisted of previously deferred revenue from retail distributors (GNC and Vitamin Cottage) recognized in the period ended September 30, 2008. This occurred because the company established sufficient history to estimate product returns reliably. Excluding this one-time recognition, organic sales for the six months were approximately $1,341,000.
- Operating Expenses: Total operating expenses increased by approximately $151,000 for the six-month period compared to the prior year, driven primarily by increased marketing, website redevelopment, and consulting fees. General and administrative expenses also rose due to higher equity-based compensation.
- Interest Expense: Net interest expense increased significantly to $170,385 for the six months ended Dec 31, 2008, compared to $75,956 in the prior year, due to the amortization of discounts and fees associated with convertible debentures issued in 2007.
- Cash Flow: Net cash used in operating activities was $502,982 for the six months ended Dec 31, 2008, a reversal from the $152,418 provided by operations in the same period in 2007. This shift was due to increased operating expenditures.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Capital Needs: Management believes current funds are sufficient to operate through at least June 30, 2009. However, the company is actively seeking to raise up to $2.5 million (including an option) via a private placement of equity commenced in January 2009 to fund a new Network Marketing Sales Channel and increase working capital.
- Strategic Shift: The company is launching a Network Marketing Sales Channel, believing the scientific nature of Protandim is best communicated in a face-to-face environment.
- Product Pipeline: Research continues on Protandim for various conditions (e.g., pulmonary hypertension, diabetes). The company plans to explore additional natural products but offers no assurance of success.
Risks and Contingencies
- Liquidity Risk: The company has a history of losses and relies on external financing. Failure to raise additional capital could force a reduction in operations.
- Marketability of Securities: The company holds $750,000 in Auction Rate Preferred Securities (ARPS). While classified as current assets due to recent redemptions, the broader liquidity crisis could impact the ability to redeem these securities within 12 months.
- Customer Concentration: One national retail distributor (GNC) comprised 59% of accounts receivable as of December 31, 2008.
- Revenue Volatility: Sales of Protandim have declined on a monthly basis since 2005 due to challenges in developing a resonant marketing message.
Investor Verification Checklist
- Deferred Revenue Impact: Verify the sustainability of revenue growth excluding the $511,000 one-time recognition of previously deferred retail revenue.
- Capital Raise Status: Confirm the progress of the January 2009 private placement offering, as the filing states no units had been sold as of the report date.
- ARPS Liquidity: Monitor the redemption status of the $750,000 in Auction Rate Preferred Securities to ensure they remain liquid current assets.
- Debt Obligations: Review the terms of the convertible debentures, specifically the redemption triggers (e.g., failure to meet reporting requirements) and the 150% redemption penalty.
- Operating Cash Burn: Assess the rate of cash consumption given the negative operating cash flow of ~$503,000 for the six-month period.